Fig. 2From: A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysisWaterfall plot of the best response in target lesion. Tumor response was assessed by the investigator according to RECIST version 1.1. OC, ovarian cancer; TNBC, triple-negative breast cancerBack to article page